Trends in gynaecologic cancer mortality and the impact of the COVID-19 pandemic in the United States

Table 3 The percentage of COVID-19 related in excess deaths in women with gynaecologic cancer in the U.S. by age group, 2020–2022

	Age Years	Pandemic Epoch 1 2020	Pandemic Epoch 2 2021	Pandemic Epoch 3 2022
	Age Years	COVID%*	COVID%*	COVID%*
Gynecologic Cancer†	Overall	30.186	19.665	16.224
	Age
	25–44 years	NA	0.000	187.562
	45–64 years	39.119	36.301	140.416
	≥ 65 years	31.551	20.164	13.453
Ovarian Cancer	Overall	57.465	32.196	18.404
	Age
	25–44 years	NA	NA	NA
	45–64 years	21.166	56.260	8.975
	≥ 65 years	28.612	12.231	8.900
Cervical Cancer	Overall	13.217	17.640	85.373
	Age
	25–44 years	NA	4.717	0.000
	45–64 years	0.000	48.236	--
	≥ 65 years	37.414	25.899	27.575
Uterine Corpus Cancer	Overall	43.844	62.892	26.744
	Age
	25–44 years	NA	NA	NA
	45–64 years	38.213	30.880	11.667
	≥ 65 years	45.830	97.497	29.875

Abbreviation: NA: not applicable
†Gynecologic cancer includes cervix uteri (International Statistical Classification of Disease and Related Health Problems, 10th revision [ICD-10] code C53); corpus uteri (ICD-10 code C54); and ovary (ICD-10 code C56)
*Denotes the percentage of COVID-19 related ASMR in excess deaths
Values higher than 100 mean that the ASMR associated with COVID-19 is greater than the ASMR of excess deaths

ISSN: 1750-9378